D7285
3′-Deoxyguanosine
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C10H13N5O4
CAS Number:
Molecular Weight:
267.24
UNSPSC Code:
41106305
PubChem Substance ID:
MDL number:
biological source
synthetic (organic)
assay
≥98% (HPLC)
form
powder
solubility
1 M NH4OH: 50 mg/mL, clear, colorless
SMILES string
NC1=NC(=O)c2ncn(C3OC(CO)CC3O)c2N1
InChI
1S/C10H13N5O4/c11-10-13-7-6(8(18)14-10)12-3-15(7)9-5(17)1-4(2-16)19-9/h3-5,9,16-17H,1-2H2,(H3,11,13,14,18)
InChI key
OROIAVZITJBGSM-UHFFFAOYSA-N
Application
3′-Deoxyguanosine (3dG) is used as a complexing ligand for enzymes, such as purine nucleoside phosphorylase (PNP), and receptors, such as G-coupled receptors, to enable structure analysis. 3′-Deoxyguanosine may be used to selectively impair transcription but not polyadenylation.
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ugo Traversa et al.
Bioorganic & medicinal chemistry, 11(24), 5417-5425 (2003-12-04)
Rat brain guanosine binding sites were studied by (i). a pharmacological approach to confirm the hypothesis of the existence of specific G-coupled receptors for guanosine (1) and, for the first time, delineate a structure-activity relationship for a series of guanosine
Juan M Traverso et al.
Molecular reproduction and development, 71(1), 107-114 (2005-03-01)
The control of protein synthesis during maturation in oocytes is mainly exerted through cytoplasmic polyadenylation of stored mRNAs. We first analyzed the polyadenylation status of cyclins A2 and B1 during in vitro maturation (IVM) of bovine oocytes, using Rapid Amplification
Robert W King et al.
Antiviral chemistry & chemotherapy, 13(6), 363-370 (2003-04-30)
The development of low molecular weight inhibitors of hepatitis C virus (HCV) replication has been hindered by the lack of a good cell-based system that models the entire HCV replication cycle. To date the only two therapies approved for the